(RTTNews) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction includes an upfront payment of $240 million and up to $60 million in sales-based milestone payments.
Following the completion of this deal, Royalty Pharma will own 100% of the tiered royalty paid by Roche on worldwide net sales of Evrysdi. The royalty structure entitles Royalty Pharma to 8% on sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding $2 billion.
Royalty Pharma will begin receiving the increased royalty in the first quarter of 2026, based on Evrysdi product sales recorded in the fourth quarter of 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
